Novel targeted approaches in non-small cell lung cancer (NSCLC)

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Ardizzoni, A ^a   Tiseo, M ^b  

^a Azienda Ospedaliera Universitaria   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; K RAS PROTEIN; NAVELBINE; PACLITAXEL; PLACEBO; PLATINUM DERIVATIVE; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ACNE; ARTICLE; ASTHENIA; BLEEDING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CROSS REACTIVITY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HEMOPTYSIS; HUMAN; HYPERTENSION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NEUTROPENIA; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME;

EID: 33745590446     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj959     Document Type: Article

References (20)

1. Carney DN. Lung cancer-time to move on from chemotherapy. N Engl J Med 2002; 346: 126-128.
2. Bunn PAJ, Franklin WA. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29 (Suppl 14): 38-44.
3. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005; 23: 3235-3242.
4. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
5. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003; 290: 2149-2158.
6. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with Erlotinib in patients with non-small cell lung cancer. J Clin Oncol 2004; 22: 3238-3247.
7. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-784.
8. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-794.
9. Gatzemeier U, Pluzanska A, Szczesna A et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22: 619s (abstr 7010).
10. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI- 774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005; Published Ahead of Print on July 25, 2005 as 10.1200/ JCO.2005.02.840.
11. Thatcher N, Chang A, Parikh P et al. ISEL: A phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens. Lung Cancer 2005; 49 (Suppl 2): S4.
12. Sheperd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132.
13. Kelly K, Gaspar LE, Chansky K et al. Low incidence of pneumonitis on SWOG 0023: A preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and gefitinib/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. J Clin Oncol 2005, 23: 634s (abstr 7058).
14. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol 2005; 23: 3227-3234.
15. Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res 2004; 10 (Suppl): 4241-4244.
16. Rosell R, Daniel C, Ramiau R et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004; 22: 620s (abstr 7012).
17. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: Prognostic and therapeutic implications. J Clin Oncol 2005; 23: 3243-3256.
18. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 2004; 22: 2184-2191.
19. Sandler AB, Gray R, Brahmer J et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial - E4599. J Clin Oncol 2005, 23: 2s (abstr 4).
20. Roy S. Herbst, David H. Johnson, Eric Mininberg et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/Epidermal Growth Factor Receptor tyrosine kinase inhibitor erlotinib for patients with recurrent Non-Small-Cell Lung Cancer. J Clin Oncol 2005, 23: 2544-2555.